Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCS-01 in Uveitic and Post Surgical Macular Edema (LEOPARD)
NCT05608837Phase 2Active, not recruiting
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of OCS-01 in uveitic macular edema (UME) and macular edema (4 arms). Primary endpoints: Central Subfield Thickness at 12 weeks and Visual Acuity at 12 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
OCS-01
03
Conditions
uveitic macular edema (UME)macular edema
Beyond the preview
Go deeper on NCT05608837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608837.